Deutetrabenazine for the treatment of Huntington's chorea. (3rd August 2018)

• Record Type: Journal Article
• Authors: Bashir, Hassaan; Jankovic, Joseph
• Is Part Of: Expert review of neurotherapeutics. Volume 18:Number 8(2018)
• Page Start: 625
• Page End: 631
• Publication Date: 2018-08-03
• Subjects: Deutetrabenazine -- tetrabenazine -- VMAT2 -- Huntington's disease -- chorea; Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1080/14737175.2018.1500178
• Languages: English
• ISSNs: 1473-7175

Abstract

ABSTRACT: Introduction : Huntington's disease (HD) is an inherited neurodegenerative disorder for which no disease-modifying treatment is currently available. Only symptomatic treatment can be offered. Chorea is the most common motor manifestation of HD and may interfere with daily activities, reduce quality of life, and cause injury. Areas covered : Deutetrabenazine is the first deuterated drug and second drug after tetrabenazine, the classic vesicular monoamine transporter type 2 (VMAT2) inhibitor, to receive approval for the treatment of chorea associated with HD. This review, based largely on a detailed PubMed search, will summarize the pharmacological properties, clinical evidence of efficacy and tolerability of deutetrabenazine in the treatment of HD chorea. Expert commentary : Due to differences in pharmacology and pharmacokinetics, deutetrabenazine has shown promise that it is at least as effective as tetrabenazine in the treatment of HD chorea but has a lower risk of adverse effects. The role of VMAT2 inhibitors in the treatment of hyperkinetic movement disorders is expanding due to their efficacy and favorable tolerability profiles.